This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Congenital Dyserythropoietic Anemia, Type Ii
Information about Congenital Dyserythropoietic Anemia, Type Ii: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Congenital Dyserythropoietic Anemia, Type Ii
Most recent studies have shown that Congenital Dyserythropoietic Anemia, Type Ii shares some biological mechanisms with anemia, anemia-hemolytic, anemia-hemolytic-congenital, aplastic-anemia, beta-thalassemia, chronic-anemia, congenital-dyserythropoietic-anemia, hemochromatosis, hemoglobinuria-paroxysmal, hemolysis-(disorder), hereditary-diseases, hereditary-spherocytosis, hyperplasia, icterus, iron-overload, liver-cirrhosis, thalassemia.
Among the many pathways, these few ones have gauged particular interests from scientists studying Congenital Dyserythropoietic Anemia, Type Ii, and have been seen in publications frequently: Anion Transport, Bilirubin Conjugation, Coagulation, Complement Activation, Conjugation, Cytokinesis, Erythrocyte Maturation, Fertilization, Gallstone Formation, Glycosylation, Immune Response, Localization, Membrane Organization, Methylation, Pathogenesis, Phagocytosis, Protein Glycosylation, Proteolysis, Secretory Pathway, Transport
Quite a number of genes have been found to play important roles in Congenital Dyserythropoietic Anemia, Type Ii, such as ATF7IP, CAD, CALD1, CD55, CD59, CDA, DFFB, G6PD, GYPA, MAN2A1, MCFD2, SEC23A, SEC23B, TF, UBL4A. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.